Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in… read more.
Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.
A shorter reproductive life span, which is determined by a woman’s age at menarche and menopause, has been associated with a number of adverse health effects, including cardiovascular… read more.
Perimenopausal women need better education and support about how their periods might change towards the end of their reproductive life, finds a new study led by UCL researchers…. read more.
Care for women with menopausal health issues should improve globally following the release of an updated Monash University-led toolkit that guides health professionals around the world in assessing… read more.
Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12 adopted a positive opinion relating to… read more.
Obesity has already been associated with a number of adverse health conditions and can interfere with a person’s quality of life. A new study suggests that, in addition… read more.
A nationwide assessment of Obstetrics and Gynecology residency programs reveals the need for more training in how to provide the best care for women going through menopause, according… read more.
Experts at UCL have teamed up with leading women’s health charities to design a new education and support programme for women across the country experiencing menopause. The National… read more.
Despite the fact that nearly 90 million women in the United States are projected to be postmenopausal by 2060, menopause remains low on the priority list of many… read more.
Astellas Pharma Inc. announced positive topline results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate… read more.
Menopause-related symptoms such as hot flashes, night sweats, mood changes, sleep disturbances, joint aches and cognitive difficulties damage the quality of life for millions of women. They also can… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
